Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783453 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 | |
| SCHEMBL30301996 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 | |
| SCHEMBL2708451 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 | |
| SCHEMBL3965862 | 0.81 | HSPB1 (0.44) | CYP1A2CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1277539 | 0.81 | CA12 (0.44) | CYP1A2TSHRCYP2D6CYP2C19CFTR | |
| SCHEMBL112046 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 | |
| SCHEMBL8180907 | 0.81 | TSHR (0.55) | CYP1A2TSHRCYP2C19NPC1RAB9A | |
| SCHEMBL29149102 | 0.81 | GABRA1 (0.43) | CES2CES1 | |
| Water SCHEMBL27821993 | 0.80 | SLC6A4 (0.46) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 | |
| SCHEMBL1977659 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A3CYP1A2TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| CN-121779224-A | Preparation method of 5-fluoro-2-iodobenzoic acid | 安庆双启医药科技有限公司 | 2026-04-03 | — | — | CN | disclosed |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| EP-4584254-A1 | ISOQUINOLONES AS PI3K INHIBITORS | OnKure, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-119798221-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-118084706-A | Synthesis method of 2- (4-hydroxyphenoxy) benzamide compound | 河北科技大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117865925-A | 3, 4-benzocoumarin compound based on complex functional aromatic hydrocarbon and preparation method and application thereof | 上海瑞苷生物科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| EP-2291377-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | SLC6A4 4069/4885SLC6A3 4461/4885CYP1A2 2115/4885 |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | SLC6A4 791/4885SLC6A3 1312/4885CYP1A2 90/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | SLC6A4 516/4885SLC6A3 477/4885CYP1A2 2758/4885 |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | SLC6A4 686/4885SLC6A3 711/4885CYP1A2 1279/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | SLC6A4 516/4885SLC6A3 477/4885CYP1A2 2758/4885 |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | SLC6A4 4618/4885SLC6A3 4600/4885CYP1A2 3754/4885 |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | SLC6A4 1995/4885SLC6A3 1463/4885CYP1A2 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.